Trulicity Market Report 2026

Trulicity Market Overview

• The Trulicity market growth in the historic period has been driven by rising type 2 diabetes prevalence, limitations of oral antidiabetics • Market expansion is supported by growth in obesity related diabetes, expanding glp-1 indications • Growth Driver: Growing Diabetes Rates Fuel Demand For Trulicity Market • Market Trend: Strategic Investments in the Trulicity Market to Meet Growing Demand • North America was the largest region in 2025.

What Is Covered Under Trulicity Market?

Trulicity is a prescription medication that contains the active ingredient dulaglutide, which is a GLP-1 (glucagon-like peptide-1) receptor agonist. It is used to improve blood sugar control in adults with type 2 diabetes, often in combination with other medications. It is administered as a once-weekly injection and may also help with weight loss and reducing the risk of cardiovascular events. The main types of trulicity are prefilled syringe package and vial package. A prefilled syringe package is a medical container that holds a single dose of medication in a syringe that is already filled by the manufacturer. This ensures accurate dosing, reduces the risk of contamination, and enhances convenience for healthcare providers and patients. It has various applications in type 2 diabetes management, glycemic control, weight management, and cardiovascular risk reduction also distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Trulicity Market Growth Forecast?

The trulicity market size is expected to see strong growth in the next few years. It will grow to $12.15 million in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growth in obesity related diabetes, expanding glp-1 indications, improved reimbursement access, increasing lifestyle disease burden, broader primary care adoption. Major trends in the forecast period include growing adoption of glp-1 receptor agonists, shift toward once weekly diabetes therapies, integration of weight management in diabetes care, expansion of cardiovascular risk reduction focus, increasing patient preference for injectable convenience.

Global Trulicity Market Segmentation

1) By Type: Prefilled Syringe Package, Vial Package 2) By Application: Type 2 Diabetes Management, Glycemic Control, Weight Management, Cardiovascular Risk Reduction 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Are The Drivers Of The Trulicity Market?

The increasing diabetes population is expected to propel the trulicity market going forward. Diabetes is a chronic medical condition marked by elevated blood sugar levels resulting from the body's inability to produce insulin effectively or to use it properly. If not managed effectively, it can result in severe complications. The rising diabetes population is attributed to urbanization, unhealthy eating patterns, physical inactivity, and genetic predisposition. The rising diabetes population creates a greater demand for effective treatments such as trulicity, which helps manage blood sugar levels and improve patient outcomes. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, in March 2023, the percentage of people with type 1 diabetes in England receiving 8 care processes at GP practices participating in the NDA rose to 43.8%, up from 35.2% in 2022. Therefore, the increasing diabetes population is driving the growth of the trulicity industry. The increasing healthcare expenditures are expected to propel the growth of the Trulicity market going forward. Healthcare expenditures refer to the total spending on medical services, prescription drugs, hospital care, and other health-related goods and services by governments, private insurers, and individuals. The rising healthcare expenditures are driven by aging populations and increased prevalence of chronic diseases, which require sustained medical treatment and ongoing pharmaceutical interventions. Higher healthcare spending directly increases demand for effective diabetes medications such as Trulicity as healthcare systems and patients allocate more resources toward managing type 2 diabetes and preventing cardiovascular complications. For instance, in February 2025, according to the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, U.S. research and development expenditures rose from $892 billion in 2022 to $940 billion in 2023, reflecting an increase of $48 billion. Therefore, increasing healthcare expenditures are driving the growth of the Trulicity industry.

Key Players In The Global Trulicity Market

Major companies operating in the trulicity market are Eli Lilly And Company, Novo Nordisk

Global Trulicity Market Trends and Insights

Major companies operating in the trulicity market are focusing on strategic investment approaches, such as biologics production facilities, to gain a competitive advantage and meet growing demand. Biologics production facilities refer to specialized manufacturing plants designed to produce biologic drugs, which are complex therapies derived from living organisms, such as monoclonal antibodies, vaccines, and cell and gene therapies. For instance, in January 2023, Eli Lilly and Company, a US-based pharmaceutical company, invested $450 million to expand its North Carolina manufacturing plant, boosting production of its diabetes drug Trulicity. This adds to a $1.7 billion investment in the facility, expected to begin production later this year, with full completion by 2027, creating 100 additional jobs. Lilly is also building two new facilities in Indiana and investing €400 million in biologics production in Ireland. Overall, the company plans to spend $2.5 billion on manufacturing capacity in the coming years to support rising demand and new product launches.

Regional Insights

North America was the largest region in the trulicity market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Trulicity Market?

The trulicity market consists of sales of trulicity (Dulaglutide) injection, trulicity 3 mg and 4.5 mg, and trulicity (Dulaglutide) 0.75 mg and 1.5 mg. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Trulicity Market Report 2026?

The trulicity market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the trulicity industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.